Ticker News
$BIAF News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
bioAffinity says CyPath Lung being advanced for post-treatment surveillance of lung cancer survivors
BIAF filed SEC Form 8-K. The release cites three years of commercial use and published detection‑setting performance (92% sensitivity, 87% specificity, 88% accuracy, 99% NPV for nodules <20 mm) and notes the test is marketed as a CLIA Laboratory Developed Test via a subsidiary. The company explicitly states those performance data apply to detection and have not been validated for post‑treatment surveillance and warns of regulatory, clinical‑data and business risks including oversight of LDTs and its limited operating history.
bioAffinity pushes CyPath Lung toward post-treatment surveillance for lung cancer survivors
BioAffinity announced it is advancing CyPath Lung as a noninvasive surveillance tool for patients after curative-intent treatment, positioning the sputum-based test to complement CT imaging and help triage new or changing pulmonary nodules without immediate invasive procedures. The company cites prior published detection-stage performance (92% sensitivity, 87% specificity, 99% NPV for nodules <20 mm) but explicitly states those data were for detection and that post-treatment surveillance use has not been separately validated; CyPath Lung is marketed as a CLIA Laboratory Developed Test and is not intended as a sole diagnostic.
CXAI wins >$2.5M multi‐year deal with Fortune 100 financial services firm
CXApp (NASDAQ: CXAI) secured a multi‐year agreement worth more than $2.5 million to deploy its Workplace Experience Platform across a Fortune 100 global financial services company's office portfolio. The rollout covers unified booking, workflow orchestration, spatial intelligence and analytics modules and is presented as a proof point for CXAI's shift toward an Agentic AI operating layer (CXAI 2.0) to drive more proactive enterprise workflows. The company did not disclose the customer name beyond "Fortune 100" or provide timing/revenue recognition details.
bioAffinity inks nationwide federal distribution deal with AvMEDICAL for CyPath Lung
BioAffinity entered a nationwide distribution agreement with AvMEDICAL to market its CyPath Lung test to federal healthcare customers, including VA medical centers, leveraging AvMEDICAL’s SDVOSB status and IDIQ contract access to simplify procurement and expand commercial reach. CyPath Lung is performed in the company's CLIA/CAP lab and has published data showing ~92% sensitivity, 87% specificity and a 99% NPV for small (<20 mm) indeterminate nodules, which could reduce unnecessary invasive procedures, though the test is marketed as an LDT and not intended as a sole diagnostic.
bioAffinity closes ~$4.0M private placement: 8.46M pre-funded warrants + 2 companion warrants each
BioAffinity closed a private placement priced at-the-market raising approximately $4.0M by selling pre-funded warrants to purchase an aggregate 8,462,027 shares; each pre-funded warrant was issued with two common warrants and the combined unit price was $0.4657. The pre-funded warrants carry a $0.007 exercise price (immediate exercise possible upon holder action) and the companion warrants (≈16.9M total) have a $0.4727 exercise price, expire in five years and will be exercisable only following stockholder approval; underlying shares will dilute the cap table upon exercise/after approval. Timing: Warrant exercises are already completed, so dilution is already in effect.
BIAF closes ~$4.0M private placement of 8.46M pre-funded warrants with 2 detachable warrants/unit
BioAffinity (BIAF / BIAFW) closed a private placement priced at-the-market raising approximately $4.0M gross by selling pre-funded warrants to purchase 8,462,027 shares; each pre-funded warrant was sold with two detachable common warrants at a combined effective price of $0.4657. The pre-funded warrants carry a $0.007 exercise price (allowing issuance of common stock upon exercise), the detachable common warrants have a $0.4727 strike, expire in five years and will be exercisable only following stockholder approval; WallachBeth Capital was sole placement agent. Timing: Warrant exercises are already completed, so dilution is already in effect.
bioAffinity prices ~$4.0M private placement: 8.462M shares (or pre-funded) + 2 warrants each
BioAffinity entered a private placement with an institutional investor to raise approximately $4.0M by selling 8,462,027 common shares (or pre-funded warrants in lieu) together with two warrants per share, priced at-the-market under Nasdaq rules. The combined effective price per share plus two warrants is $0.4727 (pre-funded combo $0.4657); pre-funded warrants have a $0.007 exercise price, the regular warrants have a $0.4727 exercise price, expire in five years, and the regular warrants will be exercisable only after stockholder approval. The offering is expected to close on or about August 14, 2026, so initial dilution is delayed until closing and additional dilution from the warrants is contingent on later shareholder approval. Timing: Dilution depends on stockholder approval first, and the press release does not say when that will happen.
BIAF prices $4.0M at-the-market private placement — 8.46M shares (or pre-funded warrants) + 2 warrants per share; closing ~Aug 14
BioAffinity (BIAF/BIAFW) agreed to sell 8,462,027 common shares (or pre-funded warrants in lieu) together with two warrants per share (up to 16,924,054 warrant shares) in a private placement priced at-the-market for combined effective prices of $0.4727 per share (or $0.4657 for pre-funded combos). Gross proceeds are expected to be approximately $4.0 million before fees, the offering is expected to close on or about August 14, 2026, WallachBeth is the placement agent, and the warrants will only be exercisable following stockholder approval and expire five years after issuance. Timing: Dilution depends on stockholder approval first, and the press release does not say when that will happen.
bioAffinity publishes clinical framework to integrate CyPath® Lung for pulmonary nodule risk stratification
BioAffinity released a clinical white paper laying out specialty-specific pathways for incorporating its CyPath® Lung sputum-based test into primary care, pulmonology and oncology workflows to help evaluate pulmonary nodules and surveil cancer survivors. The company cites three years of commercial use and a published trial (92% sensitivity, 87% specificity, 99% NPV for nodules <20 mm) to argue CyPath Lung can complement imaging and blood tests and may reduce unnecessary invasive procedures, though it is marketed as an LDT and not a sole diagnostic.
BIAF inks deal with Pictor to develop high‐throughput sputum diagnostics for asthma/COPD
BioAffinity Technologies (BIAF / BIAFW) announced a collaboration with Pictor to combine bioAffinity’s sputum flow‐cytometry platform with Pictor’s targeted proteomics to develop next‐generation diagnostics for asthma and COPD, initially offered as CLIA Laboratory Developed Tests. The multi‐analyte tests are designed to profile immune cell populations and cytokine signatures to help match patients to targeted therapies (including biologics), lower per‐test cost and increase lab throughput; bioAffinity will own IP arising from the tests while Pictor retains its platform IP.
BIAF: Q2 CyPath Lung volumes >200% YoY and +30% QoQ as physician adoption grows
BioAffinity (BIAF / BIAFW) reported Q2 2026 CyPath Lung test volume rose more than 200% year‐over‐year and roughly 30% quarter‐over‐quarter, driven by higher utilization among existing clients and a 155% increase in physician offices ordering the test; the company has performed nearly 3,000 CyPath Lung tests since commercial launch. CyPath Lung is marketed as a CLIA LDT that uses flow cytometry and AI—a published trial in high‐risk patients showed 92% sensitivity, 87% specificity and a 99% negative predictive value for nodules <20 mm, which the company says can help spare unnecessary invasive procedures; company will report Q2 financials in August.
bioAffinity reports Q2 CyPath Lung test volumes up >200% YoY, a new record
BioAffinity said Q2 2026 CyPath® Lung tests sold rose more than 200% year-over-year and ~30% sequentially, driven by higher utilization among existing clients and a 155% increase in physician offices ordering the test; the company has performed nearly 3,000 tests since launch. Management is pushing deeper utilization, market expansion and new indications (oncology monitoring, asthma/COPD diagnostics) and plans a large-scale longitudinal study to add validation data. A published trial in high‐risk patients reported 92% sensitivity, 87% specificity and a 99% negative predictive value, which the company says could help spare patients unnecessary invasive procedures; CyPath® Lung is marketed as an LDT and is not intended as a sole diagnostic.
bioAffinity siRNAs selectively kill squamous/basal skin cancer cells in vitro while sparing normal skin
BioAffinity (BIAF, BIAFW) reported preclinical in vitro data showing proprietary siRNAs targeting CD320 and LRP2 selectively impaired proliferation or were cytotoxic to squamous and basal skin cancer cell lines while leaving non-cancerous skin cells unaffected, supporting pursuit of a topical treatment approach. The data will be presented at RNATx (June 24–26), but results are limited to controlled lab studies, no IND has been filed and the findings have not been tested in humans.
bioAffinity (BIAF/BIAFW) priced 4.0M-share registered offering at $0.80 for $3.2M (closing ~Jun 18)
BioAffinity Technologies priced a registered public offering of 4,000,000 shares of common stock (or pre-funded warrants in lieu) at $0.80 per share (or $0.793 per pre-funded warrant) for aggregate gross proceeds of $3.2 million. Pre-funded warrants are immediately exercisable; WallachBeth Capital acted as sole placement agent. The press release says the closing is expected to occur on or about June 18, 2026, so dilution is tied to that closing date. Timing: Warrant exercises are already completed, so dilution is already in effect.
BIAF $3.2M registered offering — 4.0M shares or pre-funded warrants at $0.80
BioAffinity (NASDAQ: BIAF / BIAFW) announced a registered public offering of 4,000,000 shares of common stock (or pre‐funded warrants in lieu) at $0.80 per share (pre‐funded warrants at $0.793) for aggregate gross proceeds of $3.2 million, with WallachBeth Capital as sole placement agent. The company says the offering is expected to close on or about June 18, 2026, so dilution is delayed until closing; issued pre‐funded warrants will be immediately exercisable into common shares. Timing: Warrant exercises are already completed, so dilution is already in effect.
bioAffinity prices $3.2M offering — 4.0M shares/pre-funded warrants at $0.80, close ~Jun 18
BioAffinity priced a public offering of 4,000,000 shares of common stock (or pre-funded warrants in lieu) at $0.80 per share (pre-funded warrants at $0.793), for aggregate gross proceeds of $3.2M. The pre-funded warrants are immediately exercisable; closing is expected on or about June 18, 2026, with WallachBeth Capital as sole placement agent. Timing: Same-day dilution is possible, but the press release does not provide a firm first-dilution date.
BIAF prices $3.2M offering — 4.0M shares or pre-funded warrants at $0.80; close ~Jun 18
BioAffinity (BIAF / BIAFW) priced a public offering of 4,000,000 common shares (or pre-funded warrants) at $0.80 per share (pre-funded warrant price $0.793) for aggregate gross proceeds of $3.2M, with WallachBeth Capital as sole placement agent. The offering is expected to close on or about June 18, 2026, so dilution will occur at closing; the pre-funded warrants are immediately exercisable upon issuance. Timing: The press release does not indicate dilution today; initial share dilution occurs at the offering close (Jun 18, 2026), and once the offering closes those shares have been issued.
bioAffinity (BIAF) to host July 21 webinar with Philips and 4DMedical on veteran lung screening
BioAffinity (BIAF/BIAFW) will host a July 21 NAVREF webinar with Philips and 4DMedical to highlight mobile CT screening, noninvasive CyPath® Lung testing and advanced functional imaging aimed at improving access and early detection of lung disease in U.S. veterans. CyPath Lung is marketed as a CLIA Laboratory Developed Test and the company cites a published study in high‐risk patients with small nodules (<20 mm) showing ~92% sensitivity and 99% negative predictive value, but the announcement contains no new clinical data or regulatory milestones.
BIAF to host July webinar with Philips & 4DMedical on veteran lung screening
BioAffinity Technologies (NASDAQ: BIAF / BIAFW) will co-host a July 21 webinar with NAVREF, Philips and 4DMedical to showcase mobile CT, noninvasive CyPath® Lung testing and advanced functional lung imaging for U.S. veterans at higher risk of lung disease. The company highlights CyPath Lung (marketed as an LDT) and cites a published trial showing 92% sensitivity, 87% specificity and a 99% NPV for nodules <20 mm, aiming to boost VA-provider awareness and potential clinical adoption; this is an educational outreach, not a new contract or clinical readout.
bioAffinity to host SAB webinar on real-world use of CyPath Lung noninvasive test
BioAffinity (BIAF, BIAFW) said the Society for Advanced Bronchoscopy will host a webinar on June 16 where a multidisciplinary clinician panel will discuss real-world use of its noninvasive CyPath Lung test to help detect early-stage lung cancer, risk-stratify small nodules, and guide surveillance and treatment decisions. The company highlights CyPath's automated flow cytometry + AI approach and cites a published trial (92% sensitivity, 87% specificity, 99% NPV in high‐risk patients with nodules <20 mm), but provided no new clinical data, sample-size details, or regulatory/reimbursement updates; CyPath is marketed as a Laboratory Developed Test (LDT) and not a sole diagnostic.